Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients

Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-603.10.1056/NEJMra050152Search in Google Scholar

Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M. Soluble mesothelinrelated peptides levels in patients with malignant mesothelioma. Dis Markers 2012; 32: 123-31.10.1155/2012/430689Search in Google Scholar

Robinson BWS, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397-408.10.1016/S0140-6736(05)67025-0Search in Google Scholar

Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92: 587-93.10.1038/sj.bjc.6602307236208815668716Search in Google Scholar

Marinaccio A, Binazzi A, Cauzillo G, Cavone D, Zotti RD, Ferrante P, et al; Italian Mesothelioma Register (ReNaM) Working Group. Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 2007; 43: 2722-8.10.1016/j.ejca.2007.09.01817980576Search in Google Scholar

Rake C, Gilham C, Hatch J, Darnton A, Hodgson J, Peto J. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer 2009; 100: 1175-83.10.1038/sj.bjc.6604879266998919259084Search in Google Scholar

Milano MT, Zhang H. Malignant pleural mesothelioma. A population-based study of survival. J Thorac Oncol 2010; 5: 1841-8.10.1097/JTO.0b013e3181f1cf2b20975379Search in Google Scholar

Podobnik J, Kocijancic I, Kovac V, Sersa I. 3T MRI in evaluation of asbestosrelated thoracic diseases - preliminary results. Radiol Oncol 2010; 44: 92-6.10.2478/v10019-010-0027-7342368522933897Search in Google Scholar

Gill RR. Imaging of mesothelioma. Recent Results Cancer Res 2011; 189: 27-43.10.1007/978-3-642-10862-4_321479894Search in Google Scholar

Peake MD, Entwisle J, Gray SG. Malignant pleural mesothelioma: clinical presentation, radiological evaluation and diagnosis. In: O'Byrne K, Rusch V, editors. Malignant pleural mesothelioma. Oxford: Oxford University Press; 2006. p. 35-60.Search in Google Scholar

Zauderer MG, Krug LM. The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol 2011; 12: 163-72.10.1007/s11864-011-0146-4332183921404104Search in Google Scholar

Okada M, Mimura T, Ohbayashi C, Sakuma T, Soejima T, Tsubota N. Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact Cardiovasc Thorac Surg 2008; 7: 102-6.10.1510/icvts.2007.166322Search in Google Scholar

Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al; European Respiratory Society/European Society of Thoracic Surgeons Task Force. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-95.10.1183/09031936.00063109Search in Google Scholar

Eržen J, Vidmar S, Sok M, Debeljak A, Kecelj P, Kovač V, et al. Surgical treatment of malignant pleural mesothelioma. Experience in Slovenia in the interdisciplinary approach. Radiol Oncol 2005; 39: 123-31.Search in Google Scholar

Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 3007-13.10.1200/JCO.2008.20.3943Search in Google Scholar

Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371: 1685-94.10.1016/S0140-6736(08)60727-8Search in Google Scholar

Zwitter M. Dutch statistics on lung cancer: sobering experience for a new approach. J Thorac Oncol 2012; 7: 269-71.10.1097/JTO.0b013e31823ab5fbSearch in Google Scholar

Kovac V, Zwitter M, Rajer M, Marin A, Debeljak A, Smrdel U, et al. A phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for malignant pleural mesothelioma. Anticancer Drugs 2012; 23: 230-8.10.1097/CAD.0b013e32834d7a1cSearch in Google Scholar

Damhuis RA, Schroten C, Burgers JA. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J 2011; Dec 1. [Epub ahead of print]10.1183/09031936.00153611Search in Google Scholar

Debevec M, Kovač V, Debeljak A, Eržen J, Remškar Z, Kern I. [Malignant pleural mesothelioma. Analysis of patients in Slovenia 1980-1997]. [Slovenian]. Zdrav Vest 2000; 69: 599-606.Search in Google Scholar

Debeljak A, Kecelj P, Kern I, Eržen J, Kovač V, Rott T. Medical thorascopy in pleural malignant mesothelioma. In: Zaltloukal P, Petruželka L, editors. Lung Cancer. Current Topics. Prague: Monduzzi Editore; 2001. p. 81-6.Search in Google Scholar

Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 335-51.10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-ZSearch in Google Scholar

Hmeljak J, Coer A. Presence and role of Simian virus 40 (SV40) in malignant pleural mesothelioma. Radiol Oncol 2009; 43: 9-16.10.2478/v10019-009-0009-9Search in Google Scholar

Hmeljak J, Kern I, Cor A. No implication of Simian virus 40 in pathogenesis of malignant pleural mesothelioma in Slovenia. Tumori 2010; 96: 667-73.10.1177/030089161009600504Search in Google Scholar

Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008; 5: 136-47.10.1038/ncponc103918227828Search in Google Scholar

Erculj N, Kovac V, Hmeljak J, Dolzan V. The influence of platinum pathway polymorphisms on the outcome in patients with malignan pleural mesothelioma. Ann Oncol 2012; 23: 961-7.10.1093/annonc/mdr32421765044Search in Google Scholar

Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-42.10.1056/NEJMoa100067820818875Search in Google Scholar

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2629-30.10.1200/JCO.2003.11.13612860938Search in Google Scholar

Lee CW, Murray N, Anderson H, Rao SC, Bishop W. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia. Lung Cancer 2009; 64: 308-13.10.1016/j.lungcan.2008.09.00819004520Search in Google Scholar

Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999; 17: 25-30.10.1200/JCO.1999.17.1.2510458214Search in Google Scholar

Aversa SM, Favaretto AG. Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV. Clin Lung Cancer 1999; 1: 73-7.10.3816/CLC.1999.n.006Search in Google Scholar

van Haarst JMW, Baas P, Manegold C, Schouwink JH, Burgers JA, de Bruin HG, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002; 86: 342-5.10.1038/sj.bjc.6600118237522711875695Search in Google Scholar

Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87: 491-6.10.1038/sj.bjc.6600505237615512189542Search in Google Scholar

Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002; 20: 274-81.10.1200/JCO.2002.20.1.27411773179Search in Google Scholar

Favaretto AG, Aversa SM, Paccagnella A, Manzini Vde P, Palmisano V, Oniga F, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003; 97: 2791-7.10.1002/cncr.1140512767092Search in Google Scholar

Andreopoulou E, Ross PJ, O'Brien ME, Ford HE, Priest K, Eisen T, et al. The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol 2004; 15: 1406-12.10.1093/annonc/mdh35615319247Search in Google Scholar

van Meerbeeck JP, Gaafar R, Manegold C, van Klaveren RJ, van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer, Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-9.10.1200/JCO.20005.14.58916192580Search in Google Scholar

Castagneto B, Zai S, Dongiovanni D, Muzio A, Bretti S, Numico G, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2005; 28: 223-6.10.1097/01.coc.0000144852.75613.5615923792Search in Google Scholar

Berghmans T, Lafitte JJ, Paesmans M, Stach B, Berchier MC, Wackenier P, et al. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Lung Cancer 2005; 50: 75-82.10.1016/j.lungcan.2005.05.00716005104Search in Google Scholar

Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, et al. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol 2008; 26: 1465-71.10.1200/JCO.2007.14.761118349397Search in Google Scholar

Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006; 24: 1443-8.10.1200/JCO.2005.04.319016549838Search in Google Scholar

Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, et al; Pemetrexed Expanded Access Program Investigators. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer 2007; 55: 187-94.10.1016/j.lungcan.2006.09.02317092602Search in Google Scholar

Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008; 3: 756-63.10.1097/JTO.0b013e31817c73d618594322Search in Google Scholar

Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19: 370-3.10.1093/annonc/mdm50118156144Search in Google Scholar

Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008; 60: 259-63.10.1016/j.lungcan.2007.09.018270265818006112Search in Google Scholar

Hillerdal G, Sorensen JB, Sundström S, Riska H, Vikström A, Hjerpe A. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol 2008; 3: 1325-31.10.1097/JTO.0b013e31818b174d18978569Search in Google Scholar

Sørensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 2008; 99: 44-50.10.1038/sj.bjc.6604421245303418542078Search in Google Scholar

Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I, et al. Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res 2009; 29: 3441-4.Search in Google Scholar

Sørensen JB, Bech C, Sorensen P, Frank H. Phase II study of carboplatin and vinorelbine 1st line treatment in advanced malignant pleural mesothelioma. [Abstract]. J Thorac Oncol 2011; 6(6 Suppl): S1354.-5.Search in Google Scholar

Zwitter M, Kovac V, Smrdel U, Kocijancic I, Segedin B, Vrankar M. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs 2005; 16: 1129-34.10.1097/00001813-200511000-0001316222156Search in Google Scholar

Zwitter M, Kovac V, Smrdel U, Vrankar M, Zadnik V. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. J Thorac Oncol 2009; 4: 1148-55.10.1097/JTO.0b013e3181ae280f19546818Search in Google Scholar

Zwitter M, Kovac V, Rajer M, Vrankar M, Smrdel U. Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial. Anticancer Drugs 2010; 21: 662-8.10.1097/CAD.0b013e32833ab7a020453635Search in Google Scholar

Kovac V. Zwitter M. Cisplatin with Alimpta or gemcitabine in long infusion for mesothelioma (AGILI). Available: http://clinicaltrials.gov/ct2/show/NCT01281800Search in Google Scholar

Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, et al; Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52: 155-63.10.1016/j.lungcan.2006.01.00616569462Search in Google Scholar

Velez M, Arango BA, Perez CA, Santos ES. Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer. Clin Med Insights Oncol 2012; 6: 117-24.10.4137/CMO.S6248329011022412303Search in Google Scholar

Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011; 72: 73-7.10.1016/j.lungcan.2010.12.00421216487Search in Google Scholar

Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, et al. Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey. Lung Cancer 2012; 75: 360-7.10.1016/j.lungcan.2011.08.01121937142Search in Google Scholar

Goricar K, Erculj N, Zadel M, Dolzan V. Genetic polymorphisms in homologous recombination repair genes in healthy Slovenian population and their influence on DNA damage. Radiol Oncol 2012; 46: 46-53.10.2478/v10019-012-0001-7342376722933979Search in Google Scholar

Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E. Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol 2012; 7: 249-56.10.1097/JTO.0b013e318233d6a922031231Search in Google Scholar

Erculj N, Kovac V, Hmeljak J, Franko A, Dodič-Fikfak M, Dolzan V. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. Pharmacogenet Genomics 2012; 22: 58-68.10.1097/FPC.0b013e32834e357222134350Search in Google Scholar